FGF21 and metabolic syndrome: In individuals with obesity and type 2 diabetes mellitus, FGF21 analogs alleviate dyslipidemia and increase adiponectin levels, but have minimal effects on glycemic control, thereby highlighting interspecies differences in the actions of FGF21 (26).